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SUMMARY 
Atomic Absorption Spectroscopy with a Carbon Rod 
Atomiser has been used to determine serum zinc levels in 
normal subjects and in patients suffering from myocardial 
infarction and deep vein thrombosis. The results suggest 
that the condition of myocardial infarction and deep vein 
thrombosis may be associated with a reduced serum zinc 
level. 
The value of oral zinc therapy for deep vein 
thrombosis has been evaluated. A seven day supplementation 
with 15mg zinc sulphate per day is sufficient to bring 
serum zinc levels back to normal values. In addition, 
this work suggests that patients suffering from deep vein 
thrombosis may benefit clinically from a course of zinc 
supplementation• 
INTRODUCTION 
Many inorganic metals such as sodium, potassium, 
calcium and magnesium play an important role in biological 
systems. Sodium and potassium are the major cations in the 
body fluid and sodium is the major cation present in the 
extracellular fluid. These cations are responsible for 
maintaining the normal osmotic equilibrium of the cells. 
For example, in the healthy state, the volume and composi-
tion of various body fluid compartments is maintained within 
physiological limits and fluid exchanges across the cell 
wall are conducted in a state of osmotic equilibrium. If 
this equilibrium is disturbed, physiological balance of the 
system cannot be maintained and life may terminate. 
In the normal state, the concentration of sodium in the 
plasma is about 142nmol/L and hyponatremia which means a 
decreased level of sodium is associated with a variety of 
conditions such as Addison disease, dehydration, chronic 
coronary inadequacy and myocardial infarction. In some 
other conditions, hypernatremia i.e. an increased sodium 
level can occur. For example in patients with nephrotic 
syndrome^, the kidney fails to eliminate a normal amount of 
water and salt and in patients suffering from both acute 
and chronic disease of the liver the impaired renal excre-
tion of sodium is due to the inadequate removal of anti 
diuretic hormone and aldosterone from the circulation. 
In a healthy human there is a low level of potassium 
in the serum, the mean value being 4.2nmol/L. There are 
many circumstances which can lead to an abnormal accumula-
tion of potassium. For example, trauma or destruction of 
muscle cells usually lead to a massive transfer of potassium 
from the intracellular fluids to the serum. Respiratory 
distress syndrome which leads to metabolic acidosis usually 
has a high serum potassium level associated with it. Adre-
nocortical insufficiency (Addison disease) also results in 
decreased renal excretion of potassium and thus increased 
level of serum potassium are observed. Hyperaldosternism 
or the excess excretion of the aldosterone hormone results 
in a markedly reduced serum potassium level. 
Calcium is another important element in the human body 
with 90% of it located in the skeletal system. Calcium is 
maintained at a relatively constant level at about 2.5nmol/L 
in most of the body fluids. One of the most important 
function of calcium ion is its regulation of nerve and muscle 
excitability. "Calcium is essential for blood clotting and 
the formation of thromboplastin from platelet and plasma 
percursors as well as the conversion of prothrombin require 
calcium. In many diseased states, the serum concentration 
of calcium is affected, for example, high calcium levels or 
hypercalcemia is observed in hyperparathyrodism, sarcoidosis 
and Hodgkin disease. While low calcium levels or Hypocal-
cemia, is a feature of diminised parathyroid function or 
hypoparathyroidism. This lack of circulation of calcium, 
caused by decrease of parathyroid hormone, leads to a state 
of neuro-muscular hyper-irritability or tetany. A signifi-
cant decrease of calcium level also occurs in acute pancreaties. 
Magnesium ion also occupies a central role in metabolism 
as it serves as an activator of a number of enzymatic 
reactions. The serum concentration of magnesium in normals 
has a mean value of 1.25nmol/L. Magnesium exerts a neuro-
muscular effect on the nervous system, in which it causes a 
curare-like action as it decreases the sensitivities of the 
motor end plate to actylcholine and decreases the liberation 
of actylcholine at the neuromuscular junction and synpathetic 
ganglia. Many enzymes, such as hexokinase and fructokinase 
are activated by magnesium. Magnesium also serves as a co-
factor for enzymes such as leucine-amino peptidase. Low 
values of magnesium are encountered in a number of clinical 
situations such as in chronic alcoholism, in diabetic 
acidosis and in clinical hyperparathyroidism. Decreased 
levels of magnesium may be responsible for production of 
various clinical symptoms such as hyper-irritability of 
neuromuscular and central nervous system and may frequently 
cause cardiovascular abnormalities. These include tremors, 
twitching, hypercative reflexes, mental aberration, ataxia 
and hypertension. 
Other cations also play an important role in human 
metabolism, however they are present in such small amounts 
that early workers were unable to measure their precise 
concentrations with the analytical methods available at the 
time. For this reason they were often mentioned as occurring 
in "traces" and the term trace elements was used to refer 
to them. 
The first indications that trace elements are of 
importance in human physiology were obtained a century ago. 
At that time interest centred upon a number of biological 
agents which were shown to contain co-ordinated metals not 
previously suspected to be of biological significance. These 
include turacin, a copper containing porphyrin which is 
found in the feathers of birds ; hemocyanin, a copper con-
taining compound found in the blood of snails • sycotypin, 
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a zinc containing blood pigment found in mollusces and a 
vanadium containing compound present in the blood of sea 
squirts^. In the 19th century, these substances were re-
garded largely as scientific curiosities and their discovery 
did little to stimulate studies regarding the function of 7 
the metals. But in 1885 MacMunn's investigation on cell 
respiration and oxidative processes pointed the way to 
studies of metal-enzyme catalysis and of the importance of 
a range of trace metal containing metalloenzymes to the 
structural and functional integrity of living cells. During 
the first quarter of this century, progress was slow, but 
studies were initiated on the importance of iron to human 
health and nutrition and several investigations on the metal 
composition of plant and animal tissues were undertaken. 
After World War II advances in nuclear technology made it 
possible to produce radio-active metals, thus the potential 
hazard of these materials to living cells became an im-
portant issue. Information on the biological distribution 
of stable metals then became a necessary prelude to assess-
ment of the maximum safe levels of radionuclides and their 
movements in the food chain. Extensive investigation were 
then carried out on trace element levels in human and 
animal tissues. 
The second quarter of this century was notable for 
spectacular advances in our knowledge of the nutritional 
importance of trace elements. In the early 20's McHargue 
of the United States pioneered the purified diet approach 
to animal studies. His findings were most inconclusive 
because the purified diets he used were so deficient in 
other respects that even with the addition of the metals 
under study, the animals usually made poor growth or died. 
But in 1928, the Wisconsin group, led by E, B. Hart was 
successful in using the purified diet technique to demons-
trate that copper is a dietary essential for haemoglobin 
formation in the rat. Within a few years the same group 
showed that the dietary intake of manganese and zinc was 
also essential for higher animals. Other workers using the 
same techniques showed that molybdenum, selenium and chro-
mium were also essential for life. 
During the last 30 years great progress has been made 
in our understanding of the mode of action of some of the 
trace elements and their metabolic movements within the 
animal body. Most of the trace elements serve a variety of 
functions, depending upon their chemical form or combination 
and their location in the body tissues and fluids. For ex-
ample, iodine and cobalt, are two of these elements. Iodine 
is present in thyroxine and cobalt is present in vitamin Bl2 
and each is unique to its respective compound. 
The oxidation state of the trace elements and their 
characteristic concentrations must be maintained within 
narrow limits if the function and the structural integrity 
of the tissues is to be safeguarded and the growth, health, 
and fertility of the animal are to remain unimpaired. A 
trace element deficient, or an excessively high dietary 
intake results in biochemical defects and many physiological 
functions may be affected. Structural disorders may arise 
which vary with different metals and with the degree and 
duration of the dietary deficiency. Most of the trace ele-
ments function primarily as catalysts for enzymes systems 
in the cells . The roles that the trace elements play in 
enzymic reactions range from weak ionic associations, for 
2+ 2+ example, Zn and Mn ions which act as catalysts in cer-
9 
tain hydrolytic enzymes, notably the peptidases , to highly 
specified covalently bonded associations known as metallo-
enzymes. Some examples of these are carbonic anhydrase, a 
zinc metalloenzyme which occurs in erythrocytes; the cyto-
chromes which are iron metalloenzyme which are involved in 
electron transport and; pyruvate carboxylase, a manganèse 
metalloenzyme, which produces oxalactate from pyruvate. In 
the metalloenzymes the metal is firmly associated with the 
protein and there is a fixed number of atoms per molecule 
of protein which cannot be removed from this association by 
dialysis. Removal of the metal by more drastic means results 
in a loss of enzymic activity which cannot readily be re-
stored by re-addition of the metal. Some enzyme systems have 
less rigid and less specific associations with a metal and 
it is more difficult to assign precise metabolic roles to 
trace metals. Malmstrong and Rosenberg^^ defined their 
role as: 
(1) to induce or maintain the active conformation state of 
protein molecule, 
(2) to act as a bridge in the formation of a ternary complex, 
a purely coordinative role, and 
(3) to change the electronic structure of the substrate 
molecule. 
The trace elements can be divided into three groups as 
indicated by Underwood^^: the essentials; these include 
iron, copper, zinc, manganese, cobalt, molybdenum, selenium 
and chromium; the possibly essentials; nickel, vanadium, 
barium and strontium; and the nonessentials or the toxic 
metals, which are toxic to the biological system at rela-
tively low concentrations, these include arsenic, lead, 
mercury and cadmium. This last classification has little 
general application because all the trace elements are 
toxic if ingested at sufficiently high levels or are in-̂  
12 
gested for an extended period. According to Cortzias , a 
trace element can be classified as essential if it meets 
the following criteria: 
(1) it is present in healthy tissues of all living things; 
(2) its concentration is fairly constant from one animal 
to the next; 
(3) its withdrawal from the body induces the same 
structural and physiological abnormalities regardless 
of the species studied; 
(4) its addition either prevents or reverses these 
abnormalities; 
(5) the abnormalities induced by deficiency are always 
accompanied by specific biochemical changes; and 
(6) these biochemical changes can be prevented or cured 
when the deficiency is rectified. 
Absorption of all metals is regulated at the mucosa of 
the small intestine. Knowledge of the mechanism of metal 
absorption from the intestine remains fragmentary but it is 
suggested that specific proteins of low molecular weight 
appear to participate in the process. A protein associated 
with absorption of zinc has been separated and has been 
13 
shown to have a molecular weight of about 10,000 . It is 
well known that the gut is the site where metals actively 
compete with one another for the binding site of the 
proteins and that medication with iron depresses the 14 
absorption of copper in infancy . Zinc (and probably 
iron) f o m poorly soluble ternary complexes with calcium 
and phytic acid, and high intakes of calcium in the form 
of calcareous clays caused the development of iron deficiency 
in Turkish children^^ and iron and zinc deficiency in 16 Iranian children . Cobalt absorption rises with that of 
iron in iron deficiency but cobalt and iron inhibit absorp-
17 
tion of each other 
Because of their chemical similarities, cadmium, copper, 
silver, and zinc act as antagonists to one another in To 1Q 20 metabolism ' ' . They appear to compete for various 
binding sites within metabolic systems which include 
21 22 intestinal absorptions . Van Campen demonstrated that 
zinc interacts with copper at a site either in or on the 
23 24 
intestinal mucosa. Later workers ' identified a metal-
binding protein in chick duodenum and suggested that cadmium 
and zinc antagonise copper absorption by competing for 
binding sites on the intestinal proteins. These workers 
isolated and purified metallothionein from bovine duodenum 
and demonstrated that cadmium and zinc displace copper from 
sulfhydryl binding sites on the protein. Whanger and 
Weswig later presented evidence that cadmium and zinc 
25 antagonise copper metabolism within hepatic cells . They 
also demonstrated that plasma ceruplasmin is restored much 
more readily in rats fed the low-copper diet than in animals 
fed the low-copper diet supplemented with cadmium, silver 
and zinc. They further suggested that these metals in-
hibited ceruplasmin activity by preventing copper from 
inducing the aproceruplasmin molecule or by being incorporated 
into ceruplasmin in place of copper or a combination of both 
mechanisms. Examinations of the subcellular distribution 
of zinc in the liver show that dietary zinc supplements 
leads to a decreased concentration of copper within the 
microsomes and the soluble fraction while the zinc concen-
tration of these fractions increase significantly. 
In a study of the flour beetle^^, it was found that 
additional copper slightly reduced the toxic effects of 
high levels of both zinc and cadmium and that high level of 
zinc reduce the toxicity of cadmium. When cadmium was 
added to the diets of chicks, in the presence of additional 
copper, zinc or iron, alone or in combination, significant 
interactions between the metals were revealed affecting live 
weight gains, mortality, red cell counts, haemoglobin levels 
26 and cytochrome oxidase activity in the heart . Comparable 
interactions involving cadmium, zinc, copper and iron were 
27 
subsequently demonstrated in mice and rats . Cadmium 
feeding does not consistently reduce the zinc concentration 
in tissue nor does zinc feeding consistently reduce the 
cadmium concentrations, even though each element can anta-27 28 29 
gonise the toxicity effects of the other ' ' . That 
these antagonistic effects exist between cadmium and zinc 
has been demonstrated in hypertensive patients. Schroeder^^ 
has reported that there is a high cadmium/zinc ratio in the 
tissues of the hypertensive patients. When the ratio of 
cadmium to zinc in the rat kidney exceed 0.35 on a molar 
basis the animal might be expected to exhibit hypertension 
because this ratio in kidneys has been correlated with 
31 hypertensive deaths in man . The injection of disodium 
zinc cyclohexane-1, 2-diamine-N, N,N', N'-tetraacetic acid, 
lowered the ratio enough to reverse the hypertensive state 
by replacing some of the renal and hepatic cadmium with zinc. 
The Chinese probably were the first to extract zinc 
metal in 1597. It was orginally sold as "spialter" from 
which the industrial name "Spelter" derives, a term which 
now applies to less pure zinc. The element, zinc, has been 
estimated to represent 0.004% of the earth's crust and is 
the 25th in order of abundance. Zinc has the atomic number 
30 and the atomic weight 65.38. There are several isotopes, 
of which 65 with a half-life of 250 days has been most zn 
widely used for biological studies. ^^^^ ^ much 
shorter half-life, 38 minutes has been employed where this 
property is a desirable factor, as in therapeutic investi-
3 2 
gâtions . Zinc was first reported to be essential to 
animals in 1934 by Wilkert R. Todd et.al. at the University 
of Winconsin. The importance of this element to humans was 
not appreciated until 1963, when A. S. Prasad of Wayne State 
University reported the effect of zinc deficiency among 33 
adolescent boys in Egypt . Zinc is now known to be pre-
sented in at least 90 enzymes. Some of these metalloenzymes 
are pancreatic carboxypeptidase; lactic and glutamic dehy-
drogenase; alkaline phosphatase; alcohol and malic dehydro-
11 32 genases and tryptophan desmolase ' . Zinc is also 
32 34 
reported to be present in the hormone insulin ' which is 
produced by the pancreas. Zinc plays an important role in Of- o ¿r the cell division and protein synthesis ' . It is also 
32 37 involved in the functioning of the gonads ' and the 
32 
pituitary glands 
Zinc is present in serum and erythrocytes, leucocytes 
and platelets. Serum contains about 12%, leucocytes 3% and 
erythrocytes 85% of the whole blood zinc. Almost the whole 
of the zinc in erythrocytes is situated in carbonic anhy-
38 drase . Carbonic anhydrase cannot be detected in serum or . 
leucocytes, so that the zinc in erythrocytes must account 
39 
for the whole of the activity of this enzyme in blood 
Human leucocytes contain a zinc metalloprotein with no 
known enzymic activity"^^. Human blood platelets contain Q 
zinc in amounts ranging from 0.2 to 0.45 ;ig/lO platelets. 
The serum zinc content is consistently higher than that of 
plasma by an average of 16%. Of this increase, 44% was 
demonstrated as being derived from platelets during clotting, 
39% from a slightly greater dilution in plasma, and 4% from 
haemolysis'^^. Analysis has been performed on serum and 42 
plasma and was found to be equivalent^ , indicating that 
zinc is not removed by clot formation. 
Profound changes in zinc content of serum and cellular 
elements occur in various diseases. Subnormal serum zinc 
concentrations have been reported in patients with atheros-
>1 o 44 
clerosis , with malignant tumor , with myocardial in-
farction"^^, with chronic and acute infections^with 
untreated pernicious a n e m i a ^ a n d with post-alcoholic 
cirrhosis of the liver^^'^^. in patients with anemia other 
than pernicious anemia, the zinc and carbonic anhydrase 
levels in blood are lowered in parallel fashion so that the 
decreases are proportional to the decreases in haemoglobin 
and red cell (RBC) remain in normal range. In pernicious 
anemia, however, zinc and carbonic anhydrase values per 
51 
unit of RBC are found to be significantly above normal 
Zinc in trace concentration is essential for growth and 
health. 
Early microchemical methods such as the use of 52 diphenylthiocarbazone (Dithizone) or Zincon (2-carboxy-
53 
2'-hydroxy-5'-sulfo-formalzylbenzene) for the determination 
of zinc in biological fluids are time consuming and tedious. 
They usually involve an extraction, ashing and washing with 
organic solvents or a precipitation with trichloroacetic 54 55 56 acid to remove protein or other interfering substances ' ' 
57 
before analysis. The use of emission spectroscopy for 
zinc determination has been reported. The advantages of 
this approach are the high sensitivity and the small sample 
size, but the main deterrent for routine application is the 
high cost of the equipment. X-ray fluorescence was first 
used for the detection of zinc in biological samples in 
1935^^ and the method was later developed for quantitation 
of zinc in human tissues^^ and blood serum^^. Again the 
fairly high sensitivity of the method is offset by the cost 
of the equipment. Measurement of zinc in urine, serum and 6l 
tissue by polarography has also been described. Extensive 
cleanup of the sample such as extraction of zinc as the 
dithizone complex followed by ashing have to be used before 
a measurement can be made. A f luorometric method for the 
determination of zinc in serum and urine has been described 
This analysis involves the formation of a 8-quinolinol 
complex under alkaline condition after which zinc is deter-
mined by a fluorescence measurement at 5l7nm using an 
excitation at 375nm. Under these conditions magnesium and 
calcium do not interfere with the zinc measurement. The 
main disadvantage of the procedure are the large sample 
volumes and the fall off of fluorescence on sample storage. 
Walsh in 1955 described the application of the atomic 
63 absorption technique to chemical analysis . Willis later 
64 
used the technique for the determination of calcium , 
magnesium^^, sodium and potassium^^ in biological fluids. 
Since the method is specific for a given element, atomic 
absorption spectrophotometry is very suitable for trace 
analysis in biological fluids. Atomic absorption involves 
measurement of the absorption of light by the ground state 
of the metal to be determined. The light source is a 
hollow-cathode or arc discharge lamp. The solution to be 
analysed is converted by means of a stream of compressed 
air to a fine spray which is mixed with coal gas, propane, 
acetylene or hydrogen and the mixture burned in a stainless 
steel burner. The light from the lamp after transversing 
the flame, enters a monochromater which has been set at the 
wavelength of the resonance line of the metal to be deter-
mined and then falls on to a photo-multiplier. The light 
from the lamp is modulated and the signal from the photo-
multiplier is amplified and the output is read on a meter. 
Thus, because of its sensitivity, simplicity and selectivity. 
traces of one element can be accurately determined in the 
presence of other elements. Atomic absorption spectroscopy 
is an ideal method for the determination of zinc level in 
biological fluids. 
Zinc is usually firmly bound to the protein present in 
the biological fluids. Therefore, deproteinisation and 
extraction procedures are often necessary before an analysis 
can be attempted. Lee et.al.^^ used pyridine-2-aldehyde-2-
pyridyl hydrazone "PATHY" (Fig. 1) to extract the zinc from 
serxim. The technique is based on the ability of PATHY to 
form stable cationic bis-complexes with zinc, in the +2 
oxidation state in an aqueous medium. When the pH of the 
solution is adjusted towards the alkaline side, the charged 
complexes attain neutrality and are quantitatively extract-
able into an organic solvent. Thus the metals are freed of 
the interfering effects of other serum constituents and are 
easily quantitated by Atomic Absorption Spectrophotometry. 
However, this procedure is lengthy and contamination risks 
are high because large sample volumes (1ml) are necessary, 
alternatively, zinc analysis by the PATHY route has also 
been done by diluting the serum with de-ionised water^® and 
69 
with metal free buffer . This modification requires less 
sample (0.5ml), and is thus less prone to interference. 
Recent developments of non-flame atomization in atomic 
absorption spectroscopy offer the opportunity for develop-
ment of rapid methods for determination of trace metals in 
biological materials. As compared with conventional flame 
technique, non-flame atomization permits detection limits 
as low as 0.005;ig which are several orders of magnitude 
better than the conventional flame method. This also means 
that sample size of the ordeir of micirolitires is enough to 
produce a sound analysis, thus simplifying the necessary 
pretreatment of biological samples. One disadvantage of the 
non-flame method is matrix interference. Matrix inter-
ference is most common in measuring low dilutions of serum 
.against aqueous standards. They give different viscosity 
effects. Methods have been published^^ in which aqueous 
standards are rendered more viscous by the addition of high 
molecular weight substances. The most commonly used 
substance is xylene; when impregnated into the carbon rod 
it prevents samples and standards from soaking into the rod 
and makes it possible to evaporate them reproducibly from 
the inner surface of the transverse bore. It also improves 
reproducibility of measurements of aqueous solutions. 
Another disadvantage of the non-flame method is chemical 
interference which arises as a result of incomplete dis-
sociation of compounds of the analyte. Metals differ widely 
71 
in thier susceptibility to chemical interference . For 
example, calcium is highly prone to interference by phosphate 
ion, but this chemical interference can often be minimised 
by the use of higher temperature. 72 Use of a sampling boat, which was introduced in 1968 
is restricted to the determination of the most volatile 
73 74 
metals. The original type of carbon rod ' does not 
provide enough sensitivity for certain biological appli-
cations unless operated in the fluorescence mode. On the 
other hand, unless sample is diluted, the heated graphite 
tube^^ is much too sensitive for some applications (e.g. 
magnesium and zinc) even though less sensitive spectral 
lines are chosen. 
The new type of carbon rod atomizer operated in the 
atomic absorption mode is even simpler than the original 
carbon rod atomizer but gives a better absolute sensitivities 
than the heated graphite tube. Chemical and especially 
spectral interference are considerably decreased in comparison 
with the original type. The analytical range of the method 
can be considerably extended to higher concentrations by 
decreasing the sensitivity through a simple change in ex-
perimental conditions. The new type of carbon rod atomizer 
consists of a carbon rod holder and a power unit. The 
carbon rod is clamped in the holder between two water cooled 
terminals. The power unit provides the necessary operating 
current for the carbon rod in preselected sequence of drying, 
ashing and atomization cycles. The carbon rod has a trans-
verse bore 1.5mm in diameter, and is made of Ringdoff 
77 
spectroscopic RWl graphite . The sample injection hole, 
set at an angle of 30° to the longitudinal axis of the rod 
but at a right angles to the transverse bore, facilitates 
sample deposition. A sheath of nitrogen is directed around 
the rod by a chimney situates beneath. An attachment for 
slit height adjustment is used to mask the continuous 
radiations emitted by the incandescent rod. 
Before use, the rod is purified by heating to a high 
temperature. Experimental conditions for the drying cycle 
are chosen so as to remove solvent in 10 to 20 seconds by 
boiling the sample gently to prevent any losses owing to 
spluttering. The ashing is accomplished in 5 to 10 seconds 
by heating the rod to temperature lower than that at which 
the metal of interest vaporises. This removes organic 
material that would otherwise cause spectral interference 
during the subsequent atomization cycle. 
This project was concerned with the determination of 
serum zinc level in disease and healthy states using the 
technique of Atomic Absorption Spectrophotometry with non-
flame atomization. In particular we aimed to determine the 
serum zinc level of patients suffering from deep vein 
thrombosis before and after zinc therapy and of patients 
suffering from acute myocardial infarction. 
RESULTS AND DISCUSSION 
In a normal healthy individual, the serum zinc level 
is relatively constant, about 80 to iSOjag/lOOml. A zinc 
deficiency (45 to TOwg/lOOml) is associated with a number 
of clinical symptoms and these include retardation of 
growth^^'difficulties in wound healing^^; liver 
80 Rl cirrohsis ; Sickle Cell anemia ; metastic carcinoma 
83 
and acute myocardial infarction . The work in this thesis 
is concerned with the determination of zinc in the serum of 
patients suffering from acute myocardial infarction and 
deep vein thrombosis. 
In myocardial infarction, the concentration of zinc in 
the serum and the injured heart tissue seems to be lower 84 
than in normals . The decrease in the zinc level in the 
injured heart tissue perhaps relates to the disappearance 
of the enzyme lactic dehydrogenase which is a zinc metallo-
enzyme in the heart tissue. During acute myocardial 
infarction the activity of the enzyme lactic dehydrogenase 
in the serum is considerably increased while the serum zinc 
level tends to decrease. This has been ascribed to the 
fact that the rate of a reaction catalysed by an enzyme can 
be increased by the appearance of the activating substance 85 
or by the removal of inhibitors . It has been demonstrated 
that the metal which forms part of the lactic dehydrogenase 
molecule is necessary for its activity and that it will 
greatly inhibit enzyme activity when it is added to the 
purified enzyme as a cation. Subsequent removal of such ion 
will markedly activate the enzyme. Theories have been put 
forward to explain the lower zinc levels in serum in acute 
myocardial infarction. In 1972, Pakarek and co-workers 
demonstrated the presence of a heat labile, hormone-like 
protein in the polymorphonuclear leukocytes which is 
released in response to infection or tissue damage. This 
protein acts as a "leukocyte endogenous mediator (LEM)" 
and after this factor LEM is liberated from the polymorpho-
nuclear leukocyte, a net flow of amino acids to the liver 
is induced which results in an uptake of zinc by the liver 
and a decrease in serum zinc. This finding seems to 
suggest that the LEM is the factor responsible for the 
decrease of serum zinc level in the acute myocardial 
infarction, but whether zinc is coordinated to the amino 
acids is not known. 
The first experimental evidence that zinc may be 
associated with wound healing was provided by an observation 
87 
by Pories who was studying the effect of amino acids on 
wound healing. He demonstrated that rats receiving a 
phenylalanine analogue in the diet showed an accelerated 
wound healing capacity but he had difficulties in repro-
ducing his results. It was later shown that the improvement 
was due to traces of zinc in the diet. By using radio-
88 
active metals for the study of vascular wound healing, it 
was shown that there were marked differences in the 
accumulation of various radio-active metals in the healing 
artery and zinc was found to be the most active. 89 
It was shown that there is about three times as much 
zinc in the separated nuclei as in the cytoplasm. The 
apparent increase in the erythrocyte-plasma ratio was 
suggested to be a consequence of the accumulation of 
carbonic anhydrase in erythrocytes^^. ^^Zn penetrates the 
hiiman erythrocyte readily, though there is no concomitant 
91 
increase in carbonic anhydrase activity . Determinations 
of zinc content and carbonic anhydrase activity of human 
erythrocytes have suggested that they are mutually dependent 
variables. In a number of pathological conditions, the two 
parameters vary in parallel fashion, implying that a large 
percentage of the erythrocyte zinc level is due to carbonic 
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anhydrase^ . 
In normal persons as well as those afflicted with 
anemias, polycythemia-vera, secondary polycythemia, leukemia 
and congestive heart failure, both erycythrocyte zinc and 
carbonic anhydrase activity vary directly with hematocrit 
level and haemoglobin concentration. In untreated pernicious 
anemias, however, the erythrocyte zinc concentration and 
carbonic anhydrase activity are nearly normal, although the 
hematocrit value, erythrocyte count and haemoglobin levels 
are markedly decreased. The mean corpuscular zinc concen-
tration and carbonic anhydrase activity are increased 
several times more than the high mean corpuscular haemo-
globin level. In remission from this disease, zinc concen-^ 80 
tration and carbonic anhydrase activity return to normal 
The direct relationship of erythrocyte zinc levels to 
carbonic anhydrase activity of the erythrocyte was first 90 
described by Vallee et. al. However in the study of 
Dennes et. al.^^, in which radioactive ^^Zn uptake by blood 
cells was studied it was demonstrated that there is a portion 
of erythrocyte zinc which exchanges freely with the body zinc 
pool-. This suggests that some zinc is not complexed in any 
intimate chemical union with proteins of the cells whereas 
the zinc of ca.ir]Donic a.nliyclira.se is closely a.ssodateci with 
the enzyme and cannot be dialysed out of the cell even if 
94 
potent zinc chelating agents are used . Therefore it is 
not likely that easily exchanged or "labile" zinc could 
contribute to the increased concentration of erythrocyte 95 
zinc reported in certain diseases . The measured 
erythrocyte zinc probably represents the "stable" zinc, 
that is, the protein-bound zinc, which is incorporated in 
the carbonic anhydrase molecule. Some workers have shown 
that serum zinc levels are reduced in those clinical 
situations in which increased erythrocyte zinc values are 
found. This fact leads to the postulation that the "labile" 
zinc in these erythrocytes would decrease, because of the 
tendency for the "labile" zinc of the cells to be equili-
brated with the body zinc pool. 
Erythrocyte zinc tneds to be increased in those 95 
clinical states in which leukocyte zinc is decreased 
For example, greatly elevated leukocyte zinc was found in 
patient with polycythemia vera but erythrocyte zinc was 96 
less than normal. It has been reported that serum zinc 
may be increased in some cases of polycythemia vera. 
Increased binding of zinc erythrocytes may be responsible 
for reducing serum zinc in cases of megloblastic anemia, 
chronic leukemia, acute lymphocytic leukemia and myeloid 
metaplasia. Decreased serum zinc might be expected to be 
reflected first in the leukecytes, because they have rapid 
turnover and also because they ordinarily take up and bind 95 30 tò 75 times more zinc than erythrocytes 
In this study the serum zinc values of myocardial 
infarction and deep vein thrombosis patients was determined 
and compared with normal subjects. The effect of zinc 
supplementation on serum zinc levels and on the clinical 
• state of the patients was also studied. 
To establish the normal zinc levels in adult subjects, 
venous blood samples from twenty-six females and twenty-
four males within the age group of 20 to 60, were obtained 
from the Wollongong Hospital Blood Bank. After collection, 
the blood was clotted at room temperature and it was then 
centrifuged for 15 minutes. The serum was then transferred 
to a disposable plastic tube and was stored at Any 
specimen which showed even minimal signs of haemolysis was 
discarded. Twenty four hours after collection, the serum 
samples were analysed for zinc on an atomic absorption 
spectrophotometer fitted with a Carbon Rod Atomiser. Serum 
zinc values were calculated by means of calibration curves 
using zinc values of 0.5ug to 1.5ug/ml (Fig. II). 
The distribution of normal serum zinc values obtained 
from the 26 females and 24 males controls is shown in Table 
1. The mean value for the females was I02ug/l00ml and for 
the males I04ug/l00ml respectively. The variation in zinc 
values between the two sexes is less than 0.1 of the 
standard deviation, which is not statistically significant. 
The mean zinc value for the total of the 50 normals was 
105iig/l00ml with a standard deviation of the 28ug/l00ml 
giving a range of 82-l28ug/l00ml (Table 2). Our results 
are in agreement v/ith published zinc values (76-125yUg/l00ml) 
for normal serum if a correction is made to our values for 
the presence of approximately 16% disintegrated platelets 
in serum 
In order to show the within-run precision of the 
analytical method, three serum sample containing 87;ig/l00ml, 
lOOjag/lOOml and I20jug/l00ml of zinc respectively were 
analysed 10 times. The results are shown in Table 3, and 
show a coefficient of variation of less than 2%. To 
determine the recovery of added zinc, ten serum samples 
with a known zinc content taken. Their concentrations were 
80xig/l00ml; 82Mg/l00ml; 85;ug/lQ0ml; 83jag/l00ml7 85Aig/l00ml7 
75;ug/lOOml7 95Aig/l00ml; ei^g/lOOml; l03;Lig/l00ml and lllng/ 
lOOml. The samples were supplemented with an additional 
25jag/l00ml and the samples were then reanalysed. As shown 
in Table 4 the average percent recovery was 99%. The same 
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ten samples were analysed by the dithizone method to 
compare the recovery of added zinc with the carbon rod 
technique using atomic absorption spectrophotometry. As 
shown in Table 5 the mean percent recovery was 94% compared 
to 99% which was obtained with the atomic absorption method. 
A t-test was performed to see whether there is difference 
between the two methods. The t-test gave a value of 0.24, 
while in the table of t distribution at 1% confidence limit 
for one tailed test with 18 degrees of freedom has a value 
of 1-73. Thus, it showed that there was no significant 
difference between the results of the carbon rod technique 
using atomic absorption spectrophotometry and the dithizone 
colorimetric method. One valuable point which appeared in 
this comparision was that the slightly low zinc recovery in 
the dithizone method compared with the good recovery of 
zinc added in the atomic absorption method was due mostly 
to the loss of serum zinc in the original serum samples 
because of washing and extracting in the dithizone procedure. 
The results reflected the reliability and accuracy of the 
. carbon rod technique using atomic absorption spectrophotometry. 
In order to confirm that the previously reported 
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observation that patients suffering from acute myocardial 
infarction have a reduced serum zinc level, we analysed the 
serum from fifty patients from the Wollongong Hospital who 
were undergoing episodes of acute myocardial infarction. 
The patients were selected on the basis of known enzyme 
activity changes, such as creatine kinases, lactate dehy-
drogenase and aspartate transaminase. Five ml of blood was 
collected from each patient on the second day after onset 
of the myocardial infarction. In each case the blood was 
clotted and immediately centrifuged for 15 minutes and the 
serum was then transferred to a disposable plastic tube 
which was stored at 4°C. Serum samples which showed even 
minimal sign of haemolysis were discarded. All serum 
samples were analysed on the day following collections, and 
prior to analysis a standard curve was constructed using 
the standard zinc solutions (0.5-1.5;ug/l00ml) . The serum 
zinc results obtained from these patients (Table 6) yielded 
a mean value of 70;ag/l00ml with a standard deviation of 
+21.5. Our results are in good agreement with the published 
data^^^(65jLig/l00ml) obtained by a conventional flame method. 
For our study of zinc level in deep vein thrombosis, 
50 patients who suffered from this illness were investi-
gated. Of the 50 patients, 20 of them developed the throm-
bosis after an operation (Group A) and remained hospitalised 
in the Wollongong Hospital. The other 30 patients (Group B) 
who has varicose vein disease were admitted to the Wollongong 
Hospital. Blood was collected from each patient and the 
samples were analysed for zinc on the day of collection. 
The mean value of the set of results were calculated and 
they were found to be 72jLig/l00ml for Group A and 67;ug/l00ml 
for Group B. A "t" test was performed to establish if 
there were any significant difference in zinc level between 
the two groups with a 49 degree of freedom. The tables of 
t distribution for 2 tailed test at 5% significant limits 
gave a t value of 0.07, indicating that no significant 
difference existed between the two groups. On the other 
hand, the mean zinc value from the 50 patients was 70jLig/ 
lOOml with a standard deviation of 15 .2;ag/l00ml which gave 
a zinc range of 55 .3;ag/l00ml to 85 .7;Lig/l00ml. This is a 
significantly lower value than that obtained from a normal 
healthy control group. A "t" test with 98 degree of freedom 
gave a t value of 7.55 which is highly significant. Again 
our results are in agreement with previous reports that 
serum zinc levels are decreased in venous leg ulceration 
and after surgery. We have not found any reference to zinc 
levels of deep vein thrombosis and thus it seems likely 
that low serum zinc levels are associated with thrombosis 
like illness, however the mechanism for the depletion of 
serum zinc level in this condition is not known. 
It is known that 30-40% of zinc in serum is firmly 
bound to alpha2-macroglobulin while the remaining zinc seems 
to be loosely bound to albumin in normal individuals^^^'^^^. 
The amount of zinc of the alpha^-macroglobulin is decreased 
in several metabolic neoplastic disorders^^^'^^^. it 
was shown albumin readily binds ^^Zn while alpha -macro-
globulin does not take up ^^Zn or exchange it e a s i l y ^ ^ ^ ' . 
Thus the characteristics of alpha^-macroglobulin are in 
accord with those of metalloprotein such as ceruplasmin 
which contain an atom of copper. Albumin resembles more 
closely a "metal-protein-complex" such as the lactic dehy-
drogenase molecule^^^. To establish whether our patient 
group suffered from a deficiency in loosely or firmly bound 
zinc we carried out an electrophoretic separation on serum 
samples from 10 patients using cellulose acetate as a medium. 
Before the electrophorectic separation, total protein and 
albumin values were estimated by means of a Analyzer using 
biuret and bromb-cresol-green respectively. The electro-
phoresis pattern is shown in Fig. 3A and 3B. The frac-
tionated globulins were tabulated as shwon in Table 9. The 
electrophoretic pattern of this group was compared with a 
normal serum and no significant differences were found. In 
T • 0.4. ^ 4.-U • • 4. T 102,103,104,106 light of the previous experimental evidence , 
the absence of any difference in the relative proportions 
of the different electrophoretic fractions suggests that 
the decrease in zinc level in the serum of deep vein throm-
bosis patients may be due instead to a loss of zinc from the 
albumin since it normally contains a larger portion of the 
loosely bound zinc compared with the other fractions of 
^ . 102 protein 
To determine the dosage of the zinc supplement, a 
discussion was held with the doctors and surgeons at 
Wollongong Hospital, it was known that the average daily 
intake of zinc in normal adult is about 10-I5mg and that 
about 5mg of the metal is retained. As a result of the 
discussion, it was agreed to supplement the diet of the 
patients with l5mg of zinc sulphate. 
The 10 patients who suffered from deep vein thrombosis 
and who had been admitted to the ward after an operation 
were put on such an oral zinc supplement. This was given to 
the patients twice a day in the form of an aqueous solution. 
A dose was given in the morning before breakfast and a dose 
was given to the patients after dinner at night. This 
routine was maintained for a period of seven days. In each 
case, a blood sample was collected each morning before the 
administration of the zinc supplement and a total of eight 
samples were collected from each patient. 
Zinc analysis by atomic absorption spectrophotometry 
showed that this seven day treatment resulted in a signifi-
cant increase of serum zinc concentration (Table 10). It 
should be noted that serum zinc values of the patients were 
slightly increased on the third day but a more significant 
(approximately 23%) rise in zinc values was recorded on the 
fourth and the fifth day of treatment. On the seventh and 
eighth day a 45% increase of the patients serum zinc concen-
tration was recorded. These serum values were similar to 
those obtained from the serum of the control group. 
Absorbed or injected zinc is incorporated at differing 
rates into different tissues which reveal varying rates of 
zinc turnover. Uptake of zinc by the bones and CNS is 
relatively slow, and the zinc remains firmly bound for long 
periods. The most rapid accumulation and turnover rates of 
retained zinc occurs in the pancreas, liver, kidney and 
l07 1>08 
spleen ' . The zinc in these tissues and more slowly 
exchanging zinc in muscle and the red cells constitutes a 
soft tissue zinc pool composed of compartments of varying 
exchange rates. Cortias^^^' ̂ ^^ showed that various tissues 
of mice, as well as various intracellular organells of 
mouse liver cells, show distinct individuality relative to 65 time course of Zn distribution after intraperitoneal 
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injection. Injected Zn combines initially with the serum 
proteins to form a serum zinc pool and more slowly with the 
intracellular proteins of the cellular components. Following 
oral adminstration the uptake of zinc by the intestinal 
mucosa is rapid. The absorbed zinc is quickly distributed 
to combine with" the serum protein to form a serum zinc pool. 
Since zinc readily penetrates to the erythrocytes, it will 
continue to do so until they are saturated. The slow 
appearance of serum zinc concentration in the patients with 
the supplementary zinc diet (the zinc level did not appeared 
to increase to significant level until the fourth day of the 
administration) could be explained by the red cell taking up 
zinc from the initial zinc pool until it reached the normal 
level, following which distribution of the zinc to the serum 
protein appeared. 
After the course of oral supplemention of zinc sulphate, 
the patients who suffered from deep vein thrombosis were 
generally recovered. As noted by Dr. Fritzgerald the 
pathological conditions of the patients has returned to 
normal in terms of red cell counts, white cell differentials, 
haemoglobin levels and haemotocrit. Their general appetites 
have improved remarkedly. The patients were released from 
the hospital after two days of the oral supplementation 
course. 
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TABLE 1 
ZINC SERUM LEVELS OF FEMAIE AND MALE CONTROLS 
SAMPLES 
FEMALE MALE 
|ig/lOO ml. yUg/100 ml. 
1 105 107 
2 90 142 
3 84 90 
4 148 90 
5 90 80 
6 86 68 
7 108 130 
8 55 82 
9 90 132 
10 128 112 
11 110 100 
12 96 142 
13 178 120 
14 110 100 
15 90 140 
16 120 110 
17 90 100 
18 80 90 
19 130 . 110 
20 84 112 
21 100 130 
22 90 80 
23 86 110 
24 120 120 
25 100 
26 96 
X = 102 X = 104 
TABLE 2 
ZINC SERUM LEVEL OF 50 RANDOM NORMAL SERUM SAMPLES 
SAMPLES TO/10 Onil SAMPLES TO/100ml 
1 105 26 120 
2 90 27 110 
3 107 28 100 
4 84 29 90 
5 142 30 140 
6 90 31 120 
7 148 32 90 
8 90 33 80 
9 90 34 110 
10 80 35 100 
11 86 36 130 
12 .. 108 37 90 
13 68 38 84 
14 55 39 100 
15 130 40 110 
16 90 41 90 
17 128 42 86 
18 82 43 120 
19 132 44 112 
20 110 45 130 
21 112 46 100 
22 100 47 80 
23 96 48 90 
24 142 49 100 
25 178 50 120 
X = 105 
TABLE 3 
WITHIN-RUN PRECISION OF 3 SAMPLES 
EACH ANALYSED 10 TIMES USING 
THE CARBON-ROD ANALYTICAL METHOD 
SAMPLE (jag/lOOml) X S .D. C.V. 
87 87.9 1.55 1.76 
100 100.2 1.77 1.75 
120" 120.2 1.73 1.43 
TABLE 4 
RECOVERY OF ADDED ZINC IN 
10 SERUM SAMPLES WITH CARBON ROD ATOMIZER 
SAMPLES ZINC ADDED ZINC RECOVERED % RECOVERED 
Cug/lOOml) Ug/lOOml) Ug/lOOml) 
80 105 106 101 
82 107 105 98 
85 110 109 99 
83 108 107 99 
85 110 111 101 
75 - 100 99 99 
95 120 119 99 
61 86 85 99 
103 128 127 99 
117 142 143 101 
X = 99% 
TABLE 5 
RECOVERY OF ADDED ZINC IN 
10 SERUM SAMPLES WITH DITHIZONE METHOD 
SAMPLES ZINC ADDED ZINC RECOVERED % RECOVERED 
(Mg/lOOml) (;ig/lOOml) (jLig/lOOml) 
80 105 99 94 
82 107 100 93 
85 110 103 94 
83 108 102 94 
85 110 103 93 
75 100 94 93 
95 120 113 94 
61 86 81 94 
103 128 120 94 
117 142 133 93 
X = 94% 
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TABLE 6 
ZINC SERUM VALUE OF PATIENTS SUFFERING 
FROM MYOCARDIAL INFARCTION 
Samples >ig/lOOml Samples ¿15/lOOml 
1 46 26 52 
2 75 27 47 
3 82 28 82 
4 116 29 45 
5 52 30 97 
6 47 31 49 
7 52 32 75 
8 49 33 78 
9 116 34 49 
10 59 35 50 
11 52 36 64 
12 116 37 64 
13 . 82 38 66 
14 73 39 58 
15 49 40 65 
16 49 41 91 
17 99 42 91 
18 64 43 56 
19 95 44 50 
20 80 45 52 
21 94 46" 59 
22 60 47 59 
23 60 48 110 
24 101 49 71 
25 . 109 50 50 
X = 70>ig/100ml 
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TABLE 7 
ZINC SERUM VALUE OF PATIENTS SUFFERING 
FROM DEEP VEIN THROMBOSIS 
GROUP A GROUP B 
Samples Mq/lOOml Samples ^q/lOOml 
1 110 1 105 
2 97 2 78 
3 65 3 90 
4 77 4 56 
5 67 5 45 
6 80 6 65 
7 120 7 75 
8 71 8 73 
9 77 9 34 
10 56 10 82 
11 67 11 64 
12 45 12 49 
13 119 13 64 
14 34 14 49 
15 64 15 78 
16 78 16 67 
17 80 17 56 
18 64 18 69 
19 80 19 78 
20 49 20 69 
21 49 
22 56 • 
23 84 
24 67 
25 58 
26 64 
27 78 
28 69 
29 56 
30 69 
X = 72/Ag/lOOml X = 67);ig/100ml 
TABLE 8 
SERUM PROTEIN, ALBUMIN AND GLOBULIN VALUES 
OF A GROUP OF 10 PATIENTS 
Samples Total Protein Albumin Globulin 
(g/L) (g/L) (g/L) 
1 70 36 34 
2 71 36 35 
3 74 43 31 
4 71 38 33 
5 - 75 48 27 
6 76 43 33 
7 78 36 42 
8 75 48 27 
9 79 37 42 
10 72 41 31 
TABLE 9 
SERUM PROTEIN ELECTROPHORESIS 
DETERMINATION OF ALBUMIN AND FRACTIONATED GLOBULINS 
Samples Albumin Globulin 
Alpha 1 Alpha 2 Beta Gamma 
(g/L) (g/L) (g/L) (g/L) (g/L) 
1 36 2 8 12 13 
2 36 3 8 11 13 
3 43 2 6 10 13 
4 38 2 10 10 11 
5 48 2 7 10 8 
6 43 2 7 13. 11 
7 36 2 8 14 18 
8 48 2 7 10 8 
9 37 3 9 11 19 
10 41 3 6 11 11 
TABLE IO 
ZINC SERUM VALUES OF PATIENTS 
ON ORAL ZINC SULPHATE THERAPY 
Patient 
Zinc Serum Value in >ig/l00ml 
Pre-
Treatment 
Under Treatment 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
1 82 84 84 91 97 107 113 114 
2 80 85 89 92 100 102 125 128 
3 78 85 91 93 99 106 121 125 
4 67 80 82 87 101 104 114 118 
5 74 78 80 84 94 101 109 110 
6 69 72 75 78 94 99 112 114 
7 73 74 78 84 97 103 108 110 
8 75 78 81 84 92 99 110 112 
9 67 72 76 81 91 97 107 110 
10 77 80 84 88 99 103 109 119 
TABLE 11 
MEAN VALUE OF SERUM ZINC OF PATIENTS 
ON ORAL ZINC SULPHATE THERAPY 
Mean of pre-treatment zinc level 74^g/l00ml 
Mean of 4th & 5th day after treatment 
zinc level lOljug/lOOml 
Mean of 7th day after treatment zinc level 116y^g/100ml 
Increased zinc level after 4 days administration 23% 
Increased zinc level after 7 days administration 45% 
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EXPERIMENTAL 
(I) Equipment for Zinc Analysis 
An atomic absorption spectrophotometer. Model AA6 
fitted with a carbon rod atomiser. Model 63 made by 
Varian Techtron Pty. Ltd., Melbourne, Australia, was 
used for zinc analysis. The carbon rod atomiser used 
consisted of a carbon rod holder and a power unit. The 
carbon rod was clamped in the holder between two water 
cooled terminals and the power unit provided the 
necessary operating current for the rod in a pre-
selected sequence of drying, ashing and atomisation 
cycles. The atomisation cycle could be operated in 
the "step mode" when a constant selected voltage was 
for a pre-set period of time, or the "ramp mode" when 
the voltage was incremented at a pre-selected rate. 
The carbon rod had a transverse bore of 1.5mm in 
diameter, and was made of Ringsdorff spectroscopic RWl 
graphite. The sample injection hole, set at an angle 
to the transverse bore, facilitated sample deposition. 
An attachment for slit height adjustment was used to 
mask the continuous radiation emitted by the incadescent 
rod. Hollow-cathode lamps were used for this work, and 
the most sensitive analytical resonance lines were 
chosen for all determinations. 
The carbon rod was adjusted for maximum signal, 
so that the only lamp radiation reaching the detector 
was that passing through the transverse bore. If 
decreased sensitivity was required the lamp radiation 
'was focussed above the rod bore. Thus, the analytical 
range could be considerably extended to higher concen-
trations by decreasing the sensitivity through a simple 
change in experimental conditions. Before use, the rod 
was cleaned by heating to a high temperature. The 
sample was then applied to the rod, after which it was 
dried, ashed and finally atomised. Experimental con-
ditions for the drying cycle were chosen so as to 
remove any solvent by boiling the sample gently to 
prevent any losses owing to spluttering. The ashing 
was accomplished by heating the rod to a temperature 
lower than that at which the element vaporised. This 
removed organic material that would otherwise cause 
spectral interference during the subsequent atomisation 
cycle. Atomisation was achieved by finally increasing 
the temperature of the rod until all the elements to 
be measured were vaporised. The whole procedure was 
conducted by the step mode sequence. Peak signals 
were registered on a mV chart recorder. A microlitre 
syringe (S.G.E. type A-RN) was used to deliver 2ul 
samples into the carbon rod. 
The atomic absorption spectrophotometer setting 
were: lamp intensity of 5mA with the slit width of 
0.2nin; gas pressure of nitrogen of 20KPa and hydrogen 
of 20KPa. A wavelength of 213.9nM at the least 
sensitive region was used. This was achieved by 
adjusting the carbon rod bore to the height just below 
the lamp radiation source so that only minimum light 
radiation could get through. The strip chart recorder 
-was monitored at 200mV using a chart speed of 2 inches 
per minute. The gasmeter setting for the inert gas 
flow was 6.5 and for fuel input was 1.0. The settings 
of the drying cycle for the step atomisation mode 
analysis were 6V for 30 seconds for both aqueous 
standard solutions and the serum samples. While in 
the ashing cycle, the time taken for the aqueous 
standard solution was shorter than the serum samples 
because there were no organics present in the aqueous 
solution. Thus, a setting of 6V for 10 seconds were 
used for the aqueous standard solution and a setting 
of 6V for 20 seconds were used to analyse serum 
samples. For the atomisation cycle, the same settings, 
2.5V for 6 seconds, were used for both the aqueous 
standard solution and the serum samples. 
(II) Preparation of the Calibration Curve 
To establish the zinc calibration curve, a series 
of aqueous standard solutions containing 0.25, 0.50, 
1.00, 1.25 and 1.50jag/l00ml were analysed in duplicate. 
These aqueous standards were made up from a stock 
solution of zinc acetate containing Img/ml. For the 
0.5;jig/ml standard, lOul of stock solution was diluted 
with 499.90ml of de-ionised water; for the 1.0;ag/ml 
standard, 20ul of stock solution was diluted with 
499.80ml of de-ionised water; for the 1.25;ig/ml standard, 
25ul of stock solution was diluted with 499.75ml de-
ionised water; for the 1.50jag/ml standard, 30ul of 
stock solution was diluted with 499.70ml of de-ionised 
water; and for the 0.25;ag/ml standard, 250ml of 0.5;jig/ml 
- standard solution was diluted with 250ml of de-ionised 
water. Acid washed and dried volumetric flasks (500ml) 
were used for all standard solutions and 500ul of 
concentrated nitric acid (ISN) was added to each 
solution to increase stability. Before every run, a 
water blank was analysed in order to ensure that the 
carbon rod was clean. The values obtained for the 
standard solution were plotted and the line of best 
fit was drawn (Fig. 2). 
(Ill) Within Run Precision 
To establish the "within run precision" of the 
carbon rod technique, three batches of serum samples 
with different zinc concentration were each analysed 
10 times. Serum sample having a value of 87jag/l00ml, 
lOOjag/lOOml and l2Q;ag/l00ml of zinc were used. The 
values obtained were tabulated and the mean value was 
calculated. The standard deviation and the coefficient 
of variation were calculated (Table 3). 
(IV) Reproducibility and Accuracy 
A batch of 10 samples containing known zinc values 
were used in order to determine the reproducibility 
and accuracy of the method. To do this, 25ul of a zinc 
solution of known concentration was added to 10 serum 
samples concentration of each and the zinc concentrations 
were determined by atomic absorption spectrophotometry. 
The strip chart recorder results were read off from 
the standard curve and the zinc values were calculated. 
The percentage of zinc recovered for each sample was 
tabulated (Table 4). 
(V)'Dithizone Method 
(A) Determination of serum zinc by dithizone method 
was based on the method used by A . S. Prasad et.al.^^ 
All precautions to avoid contamination were carried 
out. Polyethylene test tubes and containers were 
used. De-ionised water was used for preparation of 
all reagents. Acetate buffer at pH6.3 were used. 
Chlorophenol red (O.lg in zinc free de-ionised 
water) was used as indicator solution. Seven-
tenth mg per cent dithizone in reagent grade redis-
tilled carbon tetrechloride stored in dark bottle 
at was made up freshly before use. 
1ml of serum sample was placed into a centri-
fuge tube. 1ml of zinc free 6NHC1 was delivered 
into corresponding numbered set of test tubes. 
Then 2ml of 20 per cent trichloracetic acid (TCA) 
was added to the serum samples at 90^C in a water 
bath and heated for 5 minutes with frequent 
stirring until precipitates were finely distributed. 
The tubes were cooled and centrifuged at SOOOr.p.m. 
for 20 minutes. After centrifugation, the clear 
supernatant fluids were decanted into their corres-
ponding numbered test tubes. The precipitation 
procedure were repeated twice with 2ml of 10 per 
cent TCA. The combined supernatants were then 
incubated for 1 hour at 90°C and then transferred 
into a 125ml separatory funnels, 1 drop of indicator 
was added and was titrated with NH^OH to pH5.5. 
Then 50ml of the buffer and lOml of the dithizone 
solution were added. The combined content was 
shaken vigorously for 3 minutes. The organic 
phase was read in Beckman spectrophotometer using 
CCl^ as blank. 
(B) Reagents for the dithizone method were supplied by 
Ajax Chemical Pty. Ltd., Australia. While the 
Beckman spectrophotometer Model 24 was supplied by 
the Beckman Instruments Inc., Fullerton, California, 
92634, U.S.A. 
(VI) Collection of Blood Samples 
The following equipment was used for the collection 
of blood samples: sterilised disposable syringes (Re-
gional Medical Supply Pty. Ltd., Crows Nest, N.S.W., 
Australia); 21 gauge metal venipunture needles (Regional 
Medical Supply Pty. Ltd., Crows Nest, N.S.W., Australia); 
sterilised disposable glass pipettes (Scientific Pro-
duct, McGraw Park, Illinois, U.S.A.); acid washed lOml 
sterilised glass centrifuge tubes (Scientific Product, 
McGraw Park, Illinois, U.S.A.) and lOml volume dispos-
able plastic tubes (Medical Plastic Pty. Ltd., South 
Australia, Australia). 
(VII) Collection and Storage of Normal and Patient Blood 
Samples 
Blood from twenty-six female and twenty-four male 
donors were obtained from the Blood Bank of Wollongong 
Hospital. Blood from donors who had not taken drugs 
prior to the donation was used. The blood from 
individual patients was collected with a 10ml sterilised 
plastic disposable syringe fitted with a size 21 gauge 
-metal venipunture needle. The use of such a sterilised 
syringe minimises the possibilities of contamination. 
The blood was collected from the vein and was trans-
ferred to a lOml acid washed glass centrifuge tube and 
was left to clot. After this the blood from the normal 
subjects and the patients was centrifuged for 15 
minutes at 3000rpm. Then, the sera were transferred 
to a lOml disposable plastic tube and the samples were 
then aliquoted into 1ml portions and the tubes were 
capped to prevent evaporation. The sera were stored 
in a refrigerator at 4°C. 
(VI11) Equipment for Protein and Albumin Determination 
The equipment used for protein and albumin deter-
minations was supplied by Technicon Australia and 
consisted of a Technicon Auto-analyser Model II, 6 
channel analyser fitted with a strip chart recorder. 
(IX) Protein Determination 
Serum protein determinations were done by the 
Biuret method^^^ using the Auto-analyser II Model. 
The reagents used in this method were also supplied by 
Technicon Australia. The reagents used were copper 
sulphate, potassium iodide, sodium hydroxide and 
potassium-sodium-tartrate. 
(X) Aj^^in Determination 
Serum albumin determinations were done by the 
bromo-cresol-green method^^^ using the Auto-analyser 
Model II. The reagents: sodium azide, sodium hydro-
xide, brijj 35 (a detergent solution), succinic acid 
and bromo-cresol-green used in this assay were supplied 
'by Technicon Australia. 
(XI) Equignent used for Protein AnalYsis by _E 1 ectrophore^s 
Protein electrophoresis runs were carried out on 
a Gelman Densitometer Model No. DCD 16 fitted with a 
Gelman Power Pact (Product No. 38206) which was able 
to supply a voltage output of 50-500D.C. The equipment 
was supplied by the Gelman Instrument Co., Laboratory 
Division, 600 South Wagner Road, Ann Arbor, Michigan, 
48106, U.S.A. The chart paper for the densitometer 
was also supplied by the same laboratory. The following 
equipment was supplied by Helena Laboratory, P . O . Box 
752, Beaumont, Texas, 77704, U.S.A.: the Zip-zone 
chamber (catalogue No. 1283); Super Z, 8 track appli-
cator capable of delivering lOul of serum of a single 
sample (catalogue No. 4088); Super Z sample well-plate 
(catalogue No. 4085) which consisted of 8 wells which 
could accomodate lOul serum; disposable wicks (cata-
logue No. 5081); Titan III Zip-zone cellulose acetate 
plates (catalogue No. 3023); blotting papers, 3" x 4" 
(catalogue No. 5034); plastic bags (catalogue No. 5052) 
for storage of the protein electrophoresis plates; and 
strip carrying rack (catalogue No. 5110) for delivering 
the cellulose acetate plates into the staining solution. 
The pipettes (lOul volume) used to deliver the 
serum into the applicator was supplied by Oxford 
Sampler System (catalogue No. 7000). A magnetic 
stirrer fitted with a hot plate was supplied by 
Analite Co., Australia. 
Reagents for electrophoresis were supplied by 
Helena Laboratory, P . O . Box 752, Beaumont, Texas, 
77704, U.S.A. These were: a normal serum protein 
electrophoresis control (2ml) (catalogue No. 5112); a 
serum protein electrophoresis buffer (catalogue No. 
300) which consisted of l8g of tris-barbital sodium 
barbital which after reconstitution with 750ml of de-
ionised water, yielded a solution of pH 8.0-9.0 and 
ionic strength of 0.05; a Ponceau S stain (catalogue 
No. 5525), each bottle of which consisted of a 250ml 
of 0.5% w/v of Ponceau S in an aqueous solution of 3.5% 
w/v sulfosalcylic acid and 3.5% w/v trichloroacetic 
acid and patra-clearing aid (catalogue No. 5005) which 
contained polyetheneglycol (P.E.G.). 
The other two reagents: Glacial acetic acid (AR) 
grade and absolute alcohol (AR) grade were supplied by 
Ajax Reagents Co., Sydney, Australia. 
(XII) Serum Protein Electrophoresis 
Protein electrophoresis was done by the Helena 
Laboratory standard method using cellulose acetate. 
Before each run, the cellulose acetate strips were 
pre-soaked in barbital buffers for at least 4 hours. 
The strips were then dried with blotting paper and the 
serum samples were applied to the strip by means of 
the 8 track applicator. The strips were then placed 
into the separation chamber with the cellulose acetate 
side downward touching the buffer soaked wicks. The 
chambers were filled with 50ml of barbital buffer. 
The strips were placed into the chamber in such a way 
'that the point of application was on the cathode side. 
The separation were done in 15 minutes using a voltage 
of 180V. After the run, the strips were taken out of 
the separation chamlDer and. were placed in a rack and 
stained with the Ponceau S stain solution. After 10 
minutes, the separated protein bands were fixed by the 
red stain for scanning. The strips were washed with 
5% acetic acid solution (two times). The strips were 
then soaked in alcohol for 2 minutes, followed by 
soaking in Patra-Clear solution for 5 minutes (75% of 
absolute alcohol, 20% of acetic acid and 5% of Patra-
Clear) . The strips were then placed on a clean glass 
slide with the protein bands facing upwards and they 
were then put into an incubator of 45°C for 20-30 
minutes. After drying, the strips were transferred to 
a densitometer for protein scanning. 
(XIII) Procedure for the Administration of Zinc Sulphate to 
Patients and Collection of Blood Samples 
A zinc sulphate solution containing I5mg of 
hydrated ZnSO^ was given to the patient at 7 a.m. 
before breakfast. Prior to the feeding of the oral 
supplement, venous blood (lOml) was drawn from each 
patient. The blood was collected with a sterilised 
disposable syringe (lOml) fitted with a metal veni-
punture needle. The venous blood was then transferred 
to an acid washed glass centrifuge tube and the blood 
was allowed to clot and it was then centrifuged for 
15 minutes at SOOOrpm. The unhaemolysed serum was 
then transferred to a sterilised plastic disposable 
* tube and the serum was stored in a refrigerator at 4°C. 
Another dose of zinc sulphate solution was given to 
the patient at 9 p.m. and another sample of venous 
blood (10ml) was collected next morning. The same 
treatment was repeated for a period of seven days and 
eight blood samples were taken from each patient. 
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